GlassScriptPhysician profile
David G Jones
NPI 1790855534
$3,308.12
in general payments reported to CMS, 2019-2025
28 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $420 · 2021: $545 · 2022: $583 · 2023: $335 · 2024: $371 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $844.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $389.53 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $385.14 | 2019-2024 | Rotapro, Opticross, Avvigo Guidance System |
| Janssen Pharmaceuticals, INC | $375.02 | 2019-2022 | |
| Abbott Laboratories | $293.20 | 2021-2025 | Cardiomems, Mitraclip |
| Amgen INC. | $197.81 | 2019-2021 | |
| Heartflow, INC. | $157.71 | 2022-2025 | |
| Abiomed | $102.75 | 2019 | |
| Pfizer INC. | $96.95 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $68.57 | 2019-2023 | |
| Baxter Healthcare | $67.41 | 2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $61.79 | 2020-2021 | |
| Philips North America LLC | $44.33 | 2020-2024 | (Ck4) Mcot |
| Irhythm Technologies, INC. | $36.18 | 2024 | Zio Xt Patch, Zio Monitor |
| Shockwave Medical, INC | $23.87 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $20.68 | 2025 | Barostim Neo System |
| Atricure, INC. | $18.17 | 2025 | Atriclip Laa Exclusion System, Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax |
| Lundbeck LLC | $17.71 | 2020 | |
| Cardiva Medical, INC. | $17.48 | 2025 | Cardiva Vascade 6/7f Vcs |
| Bridgebio Pharma, INC. | $16.85 | 2025 | Attruby |
| Alexion Pharmaceuticals, INC. | $16.80 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $16.35 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $15.07 | 2024 | Verquvo |
| Amarin Pharma, INC. | $12.20 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.89 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.